H-D-Dap(Boc)-OMe
Need Assistance?
  • US & Canada:
    +
  • UK: +

H-D-Dap(Boc)-OMe

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Category
BOC-Amino Acids
Catalog number
BAT-015022
CAS number
363191-25-7
Molecular Formula
C9H18N2O4
Molecular Weight
218.25
H-D-Dap(Boc)-OMe
IUPAC Name
methyl (2R)-2-amino-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate
Synonyms
3-(tert-butoxycarbonylamino)-D-alanine methyl ester; (R)-Methyl 2-amino-3-((tert-butoxycarbonyl)amino)propanoate; 3-[[(1,1-Dimethylethoxy)carbonyl]amino]-D-alanine methyl ester; 3-(N-BOC-Amino)-D-alanine methyl ester; methyl (2R)-2-amino-3-{[(tert-butoxy)carbonyl]amino}propanoate
Related CAS
919792-96-4 (free base)
Appearance
Colorless or White to Yellow Liquid or Solid
Purity
≥95%
Density
1.107±0.06 g/cm3 (Predicted)
Boiling Point
325.7±32.0°C (Predicted)
Storage
Store at -20°C
InChI
InChI=1S/C9H18N2O4/c1-9(2,3)15-8(13)11-5-6(10)7(12)14-4/h6H,5,10H2,1-4H3,(H,11,13)/t6-/m1/s1
InChI Key
AXLHVTKGDPVANO-ZCFIWIBFSA-N
Canonical SMILES
CC(C)(C)OC(=O)NCC(C(=O)OC)N
1. Synthesis and biological evaluation of analogues of the marine cyclic depsipeptide obyanamide
Wei Zhang, Ning Ding, Yingxia Li J Pept Sci. 2011 Jul;17(7):533-9. doi: 10.1002/psc.1361. Epub 2011 Apr 14.
On the basis of the total synthesis of obyanamide, 20 analogues of this marine cyclic depsipeptide have been synthesized by (i) preparation of the tripeptide fragments in the western hemisphere using Z/OtBu protocol; (ii) preparation of the dipeptide fragments in the eastern hemisphere using Boc/OMe protocol; and (iii) fragments coupling, removal of protecting groups (Boc and OtBu, in one pot), and macrocyclizaion in the last step. The cytotoxic test showed that three synthetic compounds exhibited moderate activities against HL-60, KB, LOVO, and A549 cell lines. According to the results, the β-amino acid residue was found to play a critical role in the biological activities. Additionally, the ester bond along with the Ala(Thz) moiety was also essential for biological activities. However, it seems too early to draw a conclusion that the N-methylation of Val/Phe can lead to higher or lower cytotoxic activities.
2. Effects of a specific and long-acting renin inhibitor in the marmoset
J M Wood, N Gulati, P Forgiarini, W Fuhrer, K G Hofbauer Hypertension. 1985 Sep-Oct;7(5):797-803. doi: 10.1161/01.hyp.7.5.797.
Inhibition of renin was induced in conscious marmosets with CGP 29 287, Z-Arg-Arg-Pro-Phe-His-Sta-Ile-His-Lys (Boc)-OMe, a renin inhibitor with a prolonged duration of action. In vitro, CGP 29 287 is a potent inhibitor of primate plasma renin (inhibitory concentration, 50%: human = 1 X 10(-9) M; marmoset = 5 X 10(-9) M) and less potent against dog (2 X 10(-7) M) or rat (3 X 10(-5) M) plasma renin. CGP 29 287 is a weak inhibitor of other aspartic proteases such as porcine pepsin or bovine cathepsin D (inhibitory concentration, 50% = 4 X 10(-5) M). In furosemide-treated marmosets, CGP 29 287 lowered blood pressure and inhibited plasma renin activity during intravenous infusion and after intravenous bolus injection. The duration of action after intravenous injection was dose dependent and ranged from 1 hour after 0.1 mg/kg to more than 3 hours after 10 mg/kg. High doses of CGP 29 287 (100 mg/kg) were active after oral administration. In all experiments a close relation between inhibition of plasma renin activity and reduction of blood pressure was found. A maximum hypotensive response to CGP 29 287 was associated with complete inhibition of plasma renin activity, and the recovery of blood pressure was accompanied by recovery of plasma renin activity. The hypotensive effects of CGP 29 287 were smaller in untreated than in furosemide-treated marmosets. CGP 29 287 had no influence on blood pressure in marmosets after bilateral nephrectomy or after pretreatment with a converting enzyme inhibitor.(ABSTRACT TRUNCATED AT 250 WORDS)
Online Inquiry
Verification code
Inquiry Basket